stockrow
Saturday 7 November 2026
Export RANI’s income statement to Excel — free account
Rani Therapeutics Holdings, Inc.
RANI Healthcare Biotechnology
Rani Therapeutics Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.6 million, up 58.9% from fiscal 2024.
- Revenue
- 0.00%
- EPS
- +77.8%
- Free cash flow
- −55.3%
Quarter to June 2026, against a year earlier
0.54
0.02
+3.85%
Follow RANI
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | 24.84 | 39.33 | 28.17 | |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
— | 303.69 | (20.22) | (15.76) | |
P/B ratio |
— | 2.15 | 3.70 | 2.96 | |
Price to Tangible BV |
— | 2.15 | 3.70 | 2.96 | |
EV/Sales |
— | 15.40 | 31.06 | 20.72 | |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
— | (2.96) | (6.08) | (5.16) | |
EV/FCF |
— | (2.94) | (6.06) | (5.14) | |
Quick Ratio |
0.22 | 4.08 | 3.28 | 5.21 | |
Current Ratio |
0.26 | 4.21 | 3.40 | 5.31 | |
Net Debt/EBITDA |
(1.35) | 5.89 | 5.15 | 5.97 | |
Debt/Assets |
133.51% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
(1.13) | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.08 | 0.09 | 0.13 | |
Operating CF/Net income |
0.94 | (0.03) | 0.92 | 1.22 | |
Capex/Depreciation |
0.00 | 0.00 | 0.18 | 0.28 | |
Interest Coverage |
(10.01) | (24.67) | (94.76) | (1,103.50) | |
Research and Development Expense of Revenue |
0.00% | 336.00% | 302.17% | 293.74% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 348.19% | 286.07% | 323.13% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 153.18% | 122.01% | 141.92% | |
Graham Net Nets |
— | 0.41 | 0.23 | 0.31 | |
Graham Number |
— | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
— | (43.70%) | (56.16%) | (35.53%) | |
Free Cash Flow Yield |
— | (21.06%) | (13.02%) | (14.30%) | |
Revenue per Share |
0.00 | 0.02 | 0.01 | 0.01 | |
Operating CF per Share |
(0.11) | 0.00 | (0.04) | (0.05) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.11) | 0.00 | (0.04) | (0.05) | |
Cash per Share |
0.09 | 0.75 | 0.24 | 0.29 | |
Shareholders Equity per Share |
(0.26) | 0.63 | 0.20 | 0.26 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.26) | 0.63 | 0.20 | 0.26 | |
Free Cash Flow |
(5.06) | 0.29 | (6.51) | (9.06) | |
Working Capital |
(14.19) | 40.65 | 33.24 | 45.89 | |
Capital Expenditures |
0.00 | 0.00 | (0.01) | (0.03) | |
Net Current Asset Value |
(17.16) | 36.21 | 30.76 | 43.67 | |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.02 | |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 1.08 | 1.12 | 2.37 | |
Average Payables |
2.02 | 0.83 | 1.19 | 1.42 | |
Average Assets |
26.84 | 47.63 | 38.00 | 38.87 | |
Average Common Equity |
(3.10) | 22.50 | 15.10 | 19.42 |
Columns are period end dates